Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis
暂无分享,去创建一个
T. Yamashita | S. Shibata | Yukiko Ito | Yuka Mizuno | E. Sugimoto | Shinichi Sato | H. Taira | Asumi Koyama | K. Awaji | Hiroki Matsuda | Li-xiang Li
[1] Chunping Liu,et al. Immunity: Psoriasis comorbid with atherosclerosis , 2022, Frontiers in Immunology.
[2] T. Gambichler,et al. The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review , 2022, International journal of molecular sciences.
[3] Q. Dong,et al. IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis , 2022, Frontiers in Immunology.
[4] F. Morel,et al. Ex vivo cytokine production in psoriatic disease: Towards specific signatures in cutaneous psoriasis and peripheral psoriatic arthritis , 2022, Frontiers in Immunology.
[5] P. Jankowski,et al. Investigation of the Associations of Novel Inflammatory Biomarkers—Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)—With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence , 2022, International journal of molecular sciences.
[6] D. Zillikens,et al. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases , 2022, Frontiers in Medicine.
[7] T. Gambichler,et al. Complete blood collection‐based systemic inflammation biomarkers for patients with hidradenitis suppurativa , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] Hong-Zhong Jin,et al. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients , 2021, BMC Immunology.
[9] A. Pawlik,et al. Role of Janus Kinase Inhibitors in Therapy of Psoriasis , 2021, Journal of clinical medicine.
[10] Y. Asano,et al. Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma , 2021, Acta dermato-venereologica.
[11] T. Honda,et al. Pathophysiology of psoriasis: A review , 2021, The Journal of dermatology.
[12] Shuohua Chen,et al. The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals , 2021, Journal of inflammation research.
[13] A. Yorulmaz,et al. Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis , 2020, Current health sciences journal.
[14] S. Pennington,et al. Applying precision medicine to unmet clinical needs in psoriatic disease , 2020, Nature Reviews Rheumatology.
[15] A. Armstrong,et al. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. , 2020, JAMA.
[16] Yenn-Jiang Lin,et al. Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease , 2020, European journal of clinical investigation.
[17] E. Fisher,et al. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1 , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[18] Y. Tada,et al. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review , 2020, International journal of molecular sciences.
[19] K. Schäkel,et al. Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis , 2020, Nature Communications.
[20] Asmaa M. El-Nasser,et al. Role of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Mean Platelet Volume in Egyptian Patients with Psoriasis Vulgaris. , 2020, The Egyptian journal of immunology.
[21] K. Schäkel,et al. Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis , 2019, Nature Communications.
[22] W. Boehncke,et al. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications , 2020, Frontiers in Immunology.
[23] K. Moore,et al. Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis , 2019, Science Translational Medicine.
[24] N. Korman. Management of psoriasis as a systemic disease: what is the evidence? , 2019, The British journal of dermatology.
[25] T. Hwang,et al. Neutrophils in Psoriasis , 2019, Front. Immunol..
[26] Robert A. Campbell,et al. TNF-alpha driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. , 2019, Blood.
[27] A. Mangoni,et al. Meta‐analysis of neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratio in rheumatoid arthritis , 2018, European journal of clinical investigation.
[28] A. Mangoni,et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis , 2018, Clinical and Experimental Medicine.
[29] M. Clerici,et al. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[30] T. Gambichler,et al. Interleukin‐36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop , 2018, The British journal of dermatology.
[31] J. O’Shea,et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.
[32] G. Bugdayci,et al. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Turkish patients with chronic plaque psoriasis. , 2017, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.
[33] H. Nakagawa,et al. Neutrophil–lymphocyte ratio, platelet–lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics , 2017, The Journal of dermatology.
[34] B. Goker,et al. The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis , 2016, Journal of clinical laboratory analysis.
[35] M. Afari,et al. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update , 2016, Expert review of cardiovascular therapy.
[36] Do Young Kim,et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis , 2016, The Journal of dermatology.
[37] S. Ann,et al. Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent , 2015, PloS one.
[38] T. Kadowaki,et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells , 2015, Nature Communications.
[39] A. Armstrong,et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. , 2015, JAMA dermatology.
[40] S. Clarke,et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.
[41] Ahmad H Alghadir,et al. Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis , 2012, Archives of Dermatological Research.
[42] W. Boehncke,et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.
[43] M. Karakawa,et al. Adiponectin as an anti‐inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy , 2011, The British journal of dermatology.
[44] L. Naldi,et al. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. , 2010, Clinics in dermatology.
[45] D. Mcgonagle,et al. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[46] M. Komine,et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. , 2009, Journal of dermatological science.
[47] W. Gulliver. Long‐term prognosis in patients with psoriasis , 2008, The British journal of dermatology.
[48] B. Rogala,et al. Platelet function in cutaneous diseases , 2008, Platelets.
[49] M. Gawaz,et al. Platelets in inflammation and atherogenesis. , 2005, The Journal of clinical investigation.
[50] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.
[51] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.